In November 2015, the TRIPS Council decided to extend exemptions from the pharmaceutical patent and undisclosed information protection for least developed countries until 1 January 2033 or until 1 January 2033, when they are no longer members of the least developed countries, the date when these countries are no longer members. They are also exempt from the otherwise existing obligations to accept the filing of patent applications and to grant exclusive marketing rights during the transitional period. Members of developing countries, in particular, see technology transfer as part of the good deal in which they have agreed on the protection of intellectual property rights. The ON TRIPS agreement aims to transfer technology (see above) and requires developed countries to encourage their companies to encourage technology transfer to least developed countries to enable them to create a strong and sustainable technology base. More information on technology transfer. The most visible conflict has been over AIDS drugs in Africa. Despite the role of patents in maintaining rising drug costs for public health programs across Africa, this controversy has not resulted in a review of TRIPS. Instead, an interpretive statement, the Doha Declaration, was issued in November 2001, stating that TRIPS countries should not prevent states from dealing with public health crises. After Doha, PhRMA, the United States and, to a lesser extent, other developed countries, began to work to minimize the effects of the declaration.  The TRIPS agreement introduced intellectual property rights into the multilateral trading system for the first time and remains the largest multilateral agreement on intellectual property to date. In 2001, developing countries, fearing that developed countries had insisted on too narrow a reading of the TRIPS trip, launched a series of discussions that culminated in the Doha Declaration. The Doha Declaration is a WTO DECLARATION that clarifies the scope of the TRIPS agreement, which states, for example, that TRIPS can and should be interpreted in light of the objective of “promoting access to medicines for all”.
The TRIPS agreement provides for continued negotiations within the WTO for the establishment of a multilateral system for notification and registration of geographical indications of wines, which was then extended to spirit drinks. The question of whether to negotiate the extension of this higher level of protection beyond wines and spirits is also debated in the WTO. An agreement reached in 2003 relaxed domestic market requirements and allows developing countries to export to other countries with a public health problem as long as exported drugs are not part of a trade or industrial policy.  Drugs exported under such regulations may be packaged or coloured differently to prevent them from affecting the markets of industrialized countries. The Uruguay Round has succeeded. The WTO TRIPS Agreement is an attempt to reduce gaps in the way these rights are protected and enforced around the world and to place them in common international rules. It sets minimum standards of protection and enforcement that each government must grant to the intellectual property of nationals of other WTO members. Article 10 of the agreement states that “1.
Computer programs, whether in the source code or in the object code, must be protected as literary works under the Berne Convention (1971). (2) The compilation of data or any other material, whether machine-readable or in any other form, constituting spiritual creations because of the choice or disposition of their content, must be protected as such. Such protection, which does not cover the data or material itself, does not affect the copyrights that exist in the data or materials themselves. The ON TRIPS Agreement plays a key role in facilitating the trade in knowledge and creativity, in resolving commercial disputes relating to intel property